©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Staphylococcus aureus Expresses a Major Histocompatibility Complex Class II Analog (*)

(Received for publication, June 14, 1995)

Klas Jönsson (1)(§) Damien McDevitt (1) Mary Homonylo McGavin (2) Joseph M. Patti (1) Magnus Höök (1)(¶)

From the  (1)Center for Extracellular Matrix Biology and Department of Biochemistry and Biophysics, Institute of Biosciences and Technology, Texas A & M University, Houston, Texas 77030-3303 and the (2)University of Mannitoba, Winnipeg, Manitoba R3E OW2, Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Staphylococcus aureus expresses various surface proteins which specifically recognize and bind to different host molecules. We have previously identified a bacterial protein that exhibits a broad specificity and binds to several mammalian extracellular proteins. The gene encoding this bacterial component has now been cloned and sequenced. The deduced protein consists predominantly of six repeated domains of 110 residues. Each of the repeated domains contain a subdomain of 31 residues that share striking sequence homology with a segment in the peptide binding groove of the beta chain of the major histocompatibility complex (MHC) class II proteins from different mammalian species. The purified recombinant bacterial protein bound several mammalian proteins, including recombinant osteopontin, suggesting a protein-protein interaction and also specifically recognized a 15-amino acid residue synthetic peptide. Taken together, these results suggest that the bacterial protein resembles mammalian MHC class II molecules with respect to both sequence similarities and peptide binding capabilities.


INTRODUCTION

Pathogenic bacteria have evolved in close association with their hosts and have developed sophisticated mechanisms to increase their chances of survival. Some of these mechanisms exploit normal host processes and signaling systems thus illustrating the powerful adaptation of pathogens to their environment. Some of the better examples of bacterial mimicry relate to mechanisms involved in colonization of the host. Pathogens such as Bordetella pertussis, Salmonella typhimurium, enteropathogenic Escherichia coli, and Yersinia species subvert different host systems to aid in their colonization(1, 2, 3) .

Staphylococcus aureus is an important pathogen possessing the potential to express a variety of different virulence determinants. These include exotoxins, exoenzymes, and a family of specific protein adhesins (MSCRAMMs) that mediate the adherence of the organism to host tissues and extracellular matrix components(4, 5, 6) . Some of these adhesins have been characterized in molecular detail, including the fibronectin adhesins (FnBPA and FnBPB), the collagen adhesin (Cna), and the fibrinogen adhesin (clumping factor, ClfA) (reviewed in Refs. 5 and 6). Site-specific mutants have been isolated and compared with parental strains in both in vitro and in vivo models of adherence and infection, and there is significant evidence that each of these adhesins is an important determinant for colonization and virulence(5, 6) . These proteins have similar features, including a signal peptide at the NH(2) terminus (which is cleaved during secretion across the plasma membrane) and at the COOH terminus, an LPXTG motif preceding a hydrophobic membrane spanning region, and a positively charged tail, which are involved in anchoring the proteins in the cell wall.

S. aureus also expresses several proteins which interact with the immune system. Protein A is cell wall-associated protein that comprises five (in some isolates four) repeated units of 58 amino acids, each of which can bind to the Fc region of IgG(7) . Protein A interferes with opsonophagocytosis (8) and is an important virulence factor(9, 10) . Some of the expressed toxins (enterotoxins A-E, epidermolytic toxin A, and TSST-1) act as superantigens (11) by binding to human and mouse class II major histocompatibility complex (MHC) (^1)proteins and stimulating T cells to proliferate nonspecifically(12, 13) . These superantigens can act as important mediators of toxic shock and other acute reactions.

Recently, we described a novel 72-kDa surface protein of S. aureus strain FDA 574 that is capable of binding to several extracellular matrix proteins, including fibronectin, fibrinogen, vitronectin, bone sialoprotein, and thrombospondin(14) . In this paper, we report on the molecular cloning and the complete nucleotide sequence of the gene encoding this protein. The deduced protein contains repeated subdomains that share striking sequence homology with a segment of the peptide binding groove of the beta chain of MHC class II mammalian proteins. We have designated the protein as Map (MHC class II analogous protein) and demonstrated that the purified recombinant bacterial protein specifically recognizes a 15-amino acid residue synthetic peptide derived from vitronectin.


EXPERIMENTAL PROCEDURES

Materials

E. coli strain JM101 was used as the bacterial host for plasmids and pBluescript SK(+) (Stratagene, La Jolla, CA) was used as the cloning vector. S. aureus strain FDA 574 was obtained from the United States Food and Drug Administration. Luria agar and broth (LA and LB; Difco) were used for growth of E. coli and S. aureus strains. Ampicillin (100 µg/ml) (Sigma) was added when appropriate. Restriction and modification enzymes were purchased from U. S. Biochemical Corp. or Life Technologies, Inc. Isopropyl-beta-D-thiogalactopyranoside was purchased from Life Technologies, Inc. Purified oligonucleotides were obtained from Advanced DNA Technologies Laboratory, Texas A & M University, College Station, TX. All other chemicals were molecular biology grade from Sigma or U. S. Biochemical Corp.

DNA Manipulation and Sequencing

DNA manipulations were performed using standard procedures(15, 16) . DNA was sequenced with the Sequenase 2.0 DNA sequencing Kit (U. S. Biochemical Corp.) and with the thermocycling sequencing method using the Circum Vent Thermal Cycle Dideoxy DNA Sequencing Kit (New England Biolabs). Oligonucleotides corresponding to sequences from the Bluescript clones were used as DNA sequencing primers. The final sequence was determined from both strands.

Cloning of the map Gene from S. aureus FDA 574

Polyclonal antibodies raised against the purified native Map (14) were used to screen a gt11 library constructed from genomic DNA of S. aureus FDA 574. One clone with a 5.7-kilobase pair insert was detected and called pMAP4. The NH(2)-terminal amino acid sequences of trypsin generated fragments of the native Map protein from S. aureus strain Newman were determined. These sequences were found to be almost identical to a partial sequence from the S. aureus strain ATCC 25923 OMP-70 (EMBL, accession number 13404; SAHLB.PIR; S04522). Oligonucleotides were used to PCR amplify a 360 nucleotide fragment from pMAP4. Additional gt11 clones were isolated using the random prime-labeled 200-base pair fragment corresponding to the 3` end of the 369-base pair fragment as a probe in a plaque hybridization assay. DNA from the clones was isolated and cloned into the Bluescript vector.

Expression and Purification of Native and Recombinant Map

Native Map was extracted from S. aureus FDA 574 cells with 1 M LiCl and purified as described previously(14) . The map gene was amplified from chromosomal DNA of S. aureus FDA 574 by PCR, using the primers 5`-CGGGATCCGCAGCTAAGCAAATAGATA-3` and 5`-GCGTCGACGCGGCAAATCACTTCAAGT-3`, containing the restriction cleavage sites BamHI and SalI, respectively (underlined). The reaction mixture contained 10 ng of target DNA, 200 pM of forward and reverse primers, 1.5 mM MgCl(2), 2 µM of each dNTP, 10 mM Tris-HCl, pH 9, 50 mM KCl, 0.1% Triton X-100, and 2.5 units of Taq DNA polymerase (Life Technologies, Inc.). The reaction mixtures were overlaid with 100 µl of mineral oil and amplified for 30 cycles consisting of a 1-min denaturation period at 94 °C, a 1-min anneal temperature at 55 °C, and a 1-min extension period at 72 °C. After amplification, 10 µl was analyzed by agarose gel electrophoresis (1% agarose). The PCR product was treated with SDS and proteinase K prior to digestion and ligation(17) . The product was digested with BamHI and SalI and ligated with plasmid pQE30 (Qiagen Inc.) to form pMAP1. This plasmid was transformed into E. coli strain M15 (Qiagen Inc.). A culture harboring pMAP1 was grown in LB until it reached an A of 0.6. Isopropyl-beta-D-thiogalactopyranoside was added to a final concentration of 0.5 mM, and cells were incubated at 37 °C for another 4 h. Cells were harvested, lysed by passage through a French press (twice at 20,000 pounds/inch^2), and the lysate was centrifuged at 50,000 times g for 20 min. The Map fusion protein, which contained six histidines at the amino terminus, was localized to the insoluble pellet. This pellet was solubilized in 6 M guanidine hydrochloride, and the Map fusion protein was purified by metal chelating chromatography (18) under denaturing conditions. The recombinant Map protein migrated slightly slower than the native map in SDS-polyacrylamide gel electrophoresis. Some His(6)-tagged proteins have been shown to run more slowly on SDS gels than equivalent untagged proteins(18) .

SDS-Polyacrylamide Gel Electrophoresis and Western Ligand Blotting

Proteins were fractionated on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane (Schleicher & Scheull) for 1 h at 100 V in 20 mM Tris, 150 mM glycine, 20% (v/v) methanol. Remaining binding sites were blocked for 2 h in 5% (w/v) non-fat dry milk in TBS. The filters were probed with vitronectin or with recombinant osteopontin(19) , which had been I-labeled using the chloramine-T method (20) or with fibrinogen that had been conjugated to horseradish peroxidase(21) .

Binding of Recombinant Map to Synthetic Peptides

Detachable Immulon 1 microtiter wells were coated with an increasing amount of each peptide overnight at 4 °C in 50 µl of phosphate-buffered saline (PBS). The plates were washed three times with PBS containing 0.1% Tween 20 (PBST). 100 µl of a 0.1% bovine serum albumin solution was added to the wells to block any remaining binding sites. After 1 h at room temperature, approximately 50,000 cpm I-labeled recombinant Map in 100 mM CAPS, 20 mM piperazine, pH 9.4, was added to the wells and allowed to bind for 4 h at room temperature. Following the incubation period, the wells were washed three times in PBST and then counted in a counter. The assays were performed in triplicate. Bovine serum albumin-coated wells served as a control. Results are expressed as mean ± S.D.

Peptides

I-Labeled recombinant Map was tested for binding to the following peptides: 1) vitronectin peptide, AKKQRFRHRNRKGYR, charge +8, M(r) 2001.14(22) ; 2) influenza virus peptide, PKYVKQNTLKLAT, charge +3, M(r) 1503.62(23) ; 3) cystatin-C peptide, DAYHSRAIQVVRARKQ, charge +4, M(r) 1899.03 (24) ; 4) thrombomodulin peptide, GTLGGPAQDVDFPEDRIAR, charge +2, M(r) 2014.07, 5) three thrombospondin peptides ((a) ELTGAARKGSGRRLVKGPD, charge +5, M(r) 1968.06, (b) ASLRQMKKTRGTLLALERKDHS, charge +6, M(r) 2539.73, (c) TRDLASIARLRIAKGGVNDN, charge +4, M(r) 2140.26); and 6) syndecan 4 peptide, RMKKKDEGSYDLGKKPIYKKAPTNEFYA, charge +8, M(r) 3306.39.


RESULTS AND DISCUSSION

Cloning and Nucleotide Sequence of the map Gene from S. aureus FDA 574

DNA fragments containing overlapping segments of the map gene were cloned as described under ``Experimental Procedures.'' DNA sequencing of these clones revealed a single open reading frame of 2067 nucleotides which began with an ATG at position 71 and ended with a TAA at position 2138 (Fig. 1A). The putative Map protein is composed of 689 amino acids with a predicted molecular mass of 77,040 daltons, including the signal peptide. The deduced primary structure sequence revealed a highly unusual protein that is dominated by a 110-amino acid-long domain that is repeated six times (Fig. 1B). A 30-amino acid-long signal peptide has been identified at the NH(2) terminus of the protein. The sequence coding for the 10 amino acids after the putative signal sequence corresponded exactly to the amino acid sequence obtained from the NH(2)-terminal sequence of the 1 M LiCl extracted and high performance liquid chromatography-purified native protein from S. aureus FDA 574. This sequence suggested that the signal peptide cleavage site is located after the alanine at residue 30. Following the signal peptide, there is a spacer region of 19 residues followed by the repeated domains. Typical motifs, associated with cell wall-anchored proteins and found in most Gram-positive bacterial surface proteins, were not present in the COOH terminus of the Map protein. This is in agreement with our previous study(14) , which demonstrated that the Map protein can be released from the bacterial cell surface by extraction with 1 M LiCl, suggesting that Map is not covalently anchored to the cell wall.


Figure 1: Nucleotide and deduced amino acid sequence of the map gene of S. aureus FDA 574. A, a single open reading frame of 2067 nucleotides beginning at position 71 and ending at position 2138 is indicated. The signal peptide cleavage site was determined experimentally and is indicated by a vertical arrow. The beginning of each of the 110-amino acid repeats is indicated by a horizontal arrow. B, Schematic representation of the 72-kDa Map protein of S. aureus FDA 574. The protein consists of a signal sequence (S) of 30 amino acids followed by a unique sequence (U) of 19 amino acids and six repeated domains (1-6) of approximately 110 amino acids. Within each domain there is a subdomain (shaded area) of 31 amino acids that is highly homologous to part of the peptide binding region in MHC class II DR beta molecules. The nucleotide sequence has been deposited in GeneBank(TM) (accession number U20503).



S. aureus FDA 574 Map Is Homologous to Eukaryotic MHC Class II Proteins

Within each of the six repeated 110-amino acid domains, there is a subdomain of 31 residues (Fig. 1B). These subdomains are highly homologous with the amino-terminal end of the beta chain of many MHC class II proteins from different mammalian species (Fig. 2). For example, when compared with the amino-terminal end of the beta chain of HLA-DR-9a, the respective subdomains were 48, 48, 29, 28, 39, and 10% identical. However, if conservative amino acid substitutions are included, the respective subdomains were 61, 65, 52, 59, 52, and 45% similar. The three-dimensional structure of the human MHC antigen HLA-DR1 has been determined(25) . The binding site for peptides has been located to a groove composed of 8 beta sheet strands flanked by two antiparallel helical walls at the amino-terminal end of the alphabeta heterodimer. It was concluded that conserved as well as highly polymorphic amino acids participate in peptide binding within the groove(25, 26) . The region in the beta chain of MHC class II molecules, which is homologous to the subdomains of Map, contains residues involved in peptide binding.


Figure 2: Sequence comparison of the six deduced 31 amino acid subdomains from S. aureus FDA 574 Map with part of the peptide binding region of various MHC class II DR beta chain molecules from human, mouse, and monkey. The amino acid sequences of the six homologous subdomains were aligned with the NH(2) terminus of the beta chain of MHC class II DR molecules from human, mouse, and monkey. The identical amino acids are shown in bold.



Western Ligand Blotting Analysis of Purified Native and Recombinant Map

The remarkable sequence similarity between the S. aureus FDA 574 Map protein and the eukaryotic MHC class II molecules suggested (a) that the reported binding of Map to several matrix proteins may be due to the recognition of specific and possibly similar peptide sequences in these matrix proteins rather than to other common structural features such as carbohydrates and (b) that Map might be capable of binding to small peptides in an analogous fashion to MHC class II molecules. To examine these hypotheses, recombinant Map was expressed in E. coli as a fusion protein with a polyhistidine tail and purified by metal-chelating chromatography (Fig. 3, lane 2). Both native and purified recombinant Map protein bound to labeled vitronectin, fibrinogen, recombinant osteopontin (Fig. 3, lanes 3-8), and fibronectin (data not shown). The recombinant osteopontin was analyzed by electrospray mass spectroscopy and shown to have a mass that corresponds to the predicted amino acid sequence. Hence, the protein has not been subjected to any post-translational modifications. Therefore, the binding of I-labeled recombinant osteopontin, which does not contain any additional moieties, indicates that Map binding to the matrix protein involves a specific protein-protein interaction.


Figure 3: Western affinity blot analysis of native and purified recombinant S. aureus FDA 574 Map protein. Lanes 1, 3, 5, and 7, purified native Map from S. aureus FDA 574; lanes 2, 4, 6, and 8, recombinant affinity-purified Map. Samples were stained with Coomassie Brilliant Blue R-250 (lanes 1 and 2) or probed with I-labeled vitronectin (lanes 3 and 4), horseradish peroxidase-labeled fibrinogen (lanes 5 and 6), and I-labeled recombinant osteopontin (lanes 7 and 8). Migration distances and molecular masses (kDa) of the standard proteins are indicated by the numbers on the left.



Binding of Map to a Synthetic Peptide

To investigate whether Map is capable of binding to short peptides, purified recombinant Map was labeled with I and studied for binding to a panel of eight immobilized synthetic peptides in an enzyme-linked immunosorbent assay type assay. Radiolabeled Map bound to a 15-amino acid peptide (residues 347-361 of vitronectin) (Fig. 4). This sequence contains the heparin binding domain of vitronectin, and this peptide was previously found to partially inhibit the adherence of S. aureus to immobilized vitronectin(22) . The binding of I-labeled Map to immobilized peptide increased when increasing amounts of peptide were used to coat the microtiter wells (Fig. 4). In a Western affinity blot assay, binding of the I-labeled vitronectin peptide to both native and recombinant Map could also be detected (data not shown). The Map protein failed to bind to the other seven peptides tested. Some of these peptides were of similar size and charge as the vitronectin peptide, suggesting a specific interaction between Map and the vitronectin peptide.


Figure 4: Binding of I-labeled purified recombinant S. aureus FDA 574 Map protein to synthetic peptides. Purified recombinant S. aureus FDA 574 Map bound to a vitronectin peptide (AKKQRFRHRNRKGYR) (bullet) but failed to bind to seven other peptides (listed under ``Experimental Procedures''), including an influenza virus peptide (PKYVKQNTLKLAT) () and a rat cystatin-C peptide (DAYHSRAIQVVRARKQ) ().



Previous studies have shown that S. aureus can bind a number of different host proteins (reviewed in (5) ). In some cases, the bacterial proteins have been characterized and shown to be unique proteins which are different from the Map protein. However, in many cases the bacterial proteins have not been identified and the Map protein could be responsible for some of the observed binding activities. The Map protein is, to our knowledge, the first identified structural and functional bacterial ``analog'' to mammalian MHC class II molecules and may potentially interfere with the immune defense system of the host. The mechanism and consequence of such interference is at this point speculative and is the topic of future investigations.


FOOTNOTES

*
This study was supported by National Institutes of Health Grants HL47313 and AI20624 and by the Arthritis Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) U20503[GenBank].

§
Present address: Dept. of Natural Sciences, Kalmar University, Kalmar, Sweden.

To whom correspondence and reprint requests should be addressed: Institute of Biosciences and Technology, 2121 West Holcombe Blvd., Houston, TX 77030-3303. Tel.: 713-677-7551; Fax: 713-677-7576; mhook{at}ibt.tamu.edu.

(^1)
The abbreviations used are: MHC, major histocompatibility complex; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; CAPS, 3-(cyclohexylamino)propanesulfonic acid.


ACKNOWLEDGEMENTS

We thank Dr. Charles Arntzen for comments on the manuscript.


REFERENCES

  1. Bliska, J. B., Galan J. E., and Falkow, S. (1993) Cell 73,903-920 [Medline] [Order article via Infotrieve]
  2. Finlay, B. B., and Falkow, S. (1989) Microbiol. Rev. 53,210-230
  3. Sandros, J., and Tuomanen, E. (1993) Trends Microbiol. 1,192-196 [Medline] [Order article via Infotrieve]
  4. Freer, J. H., and Arbuthnott, J. P. (1983) Pharmocol. Ther. 19,55-106
  5. Patti, J. M., Allen, B. L., McGavin, M. J., and Höök, M. (1994) Annu. Rev. Microbiol. 48,585-617 [CrossRef][Medline] [Order article via Infotrieve]
  6. Foster, T. J., and McDevitt, D. (1994) Infections Associated with Indwelling Medical Devices (Bisno, A. L., and Walvogel, F. A, eds) 2nd Ed., pp. 31-44, ASM Press, Washington, D. C.
  7. Uhlen, M., Guss, B., Nilsson, B., Gatenbeck, S., Philipson, C., and Lindberg, M. (1984) J. Biol. Chem. 259,1695-1702 [Abstract/Free Full Text]
  8. Gemmell, C. G., Tree, R., Patel, A., O'Reilly, M., and Foster, T. J. (1990) Zentralbl. Suppl. 21,231-236
  9. Patel, A. H., Nowlan, P., Weavers, E. D., and Foster, T. J. (1987) Infect. Immun. 55,3130-3110
  10. Foster, T. J., O'Reilly, M., Phonimdaeng, P., Cooney, J., Patel, A. H., and Bramley, A. J. (1990) in Molecular Biology of the Staphylococci (Novich, R. P., ed) pp. 403-417, VCH Cambridge, New York
  11. Schlievert, P. M. (1993) J. Infect. Dis. 167,997-1002 [Medline] [Order article via Infotrieve]
  12. Kim, J., Urban, R. G., Stromiger, J. L., and Wiley, D. C. (1994) Science 266,1870-1874 [Medline] [Order article via Infotrieve]
  13. Jardetzky, T. S., Brown, J. H., Gorga, J. C., Stern, L. J., Urban, R. G., Chi, Y., Stauffacher, C., Strominger, J. L., and Wiley, D. C. (1994) Nature 368,711-718 [CrossRef][Medline] [Order article via Infotrieve]
  14. Homonylo McGavin, M., Krajewska-Pietrasik, D., Ryden, C., and Höök, M. (1993) Infect. Immun. 61,2479-2485 [Abstract]
  15. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  16. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A., Seidman, J. G., and Struhl, K. (1991) Current Protocols in Molecular Biology , Greene Publishing and Wiley-Intersciences, New York
  17. Crowe, J. S., Cooper, H. J., Smith, M. A., Simms, M. J., Parker, D., and Gewert, D. (1990) Nucleic Acids Res. 19,184 [Medline] [Order article via Infotrieve]
  18. Schon, U., and Schumann, W. (1994) Gene (Amst.) 147,91-94 [CrossRef][Medline] [Order article via Infotrieve]
  19. McFarland, R. J., Garza, S., Butler, W. T., and Höök, M. (1995) Ann. N. Y. Acad. Sci. 760,327-330 [Medline] [Order article via Infotrieve]
  20. Hunter, W. M. (1978) Handbook of Experimental Immunology , (Weir, D. M., ed) pp. 14.1-14.40, Blackwell Scientific Publications, Ltd., Oxford
  21. McDevitt, D., Vaudaux, P., and Foster, T. J. (1992) Infect. Immun. 60,1514-1523 [Abstract]
  22. Liang, O. D., Flock, J. I., and Wadström, T. (1994) J. Biochem. (Tokyo) 116,457-463 [Abstract]
  23. Rothbard, B. B., and Gefter, M. L. A. (1991) Rev. Immunol. 9,527-565 [CrossRef]
  24. Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Apella, E., Grey, H. M., and Sette, A. (1992) Science 256,1817-1820 [Medline] [Order article via Infotrieve]
  25. Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993) Nature 364,33-39 [CrossRef][Medline] [Order article via Infotrieve]
  26. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1994) Nature 368,215-221 [CrossRef][Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.